174 related articles for article (PubMed ID: 29054983)
1. ALK Inhibitor Response in Melanomas Expressing
Couts KL; Bemis J; Turner JA; Bagby SM; Murphy D; Christiansen J; Hintzsche JD; Le A; Pitts TM; Wells K; Applegate A; Amato C; Multani P; Chow-Maneval E; Tentler JJ; Shellman YG; Rioth MJ; Tan AC; Gonzalez R; Medina T; Doebele RC; Robinson WA
Mol Cancer Ther; 2018 Jan; 17(1):222-231. PubMed ID: 29054983
[TBL] [Abstract][Full Text] [Related]
2. Correlation of novel ALK
Shah KK; Neff JL; Erickson LA; Jackson RA; Jenkins SM; Mansfield AS; Moser JC; Harris AL; Copland JA; Halling KC; Flotte TJ
Histopathology; 2020 Oct; 77(4):601-610. PubMed ID: 32564377
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
Choi YL; Takeuchi K; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Hamada T; Haruta H; Watanabe H; Kurashina K; Hatanaka H; Ueno T; Takada S; Yamashita Y; Sugiyama Y; Ishikawa Y; Mano H
Cancer Res; 2008 Jul; 68(13):4971-6. PubMed ID: 18593892
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
5. Acral Lentiginous Melanoma Harboring a
Couts KL; McCoach CE; Murphy D; Christiansen J; Turner J; Lewis KD; Robinson WA; Doebele RC
JCO Precis Oncol; 2017 Nov; 1():1-7. PubMed ID: 35172482
[TBL] [Abstract][Full Text] [Related]
6. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract][Full Text] [Related]
7. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
[TBL] [Abstract][Full Text] [Related]
8. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
9. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
11. BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
Turner JA; Bemis JGT; Bagby SM; Capasso A; Yacob BW; Chimed TS; Van Gulick R; Lee H; Tobin R; Tentler JJ; Pitts T; McCarter M; Robinson WA; Couts KL
Oncogene; 2019 Feb; 38(8):1296-1308. PubMed ID: 30254212
[TBL] [Abstract][Full Text] [Related]
12. ALK
Xu BS; Chen HY; Que Y; Xiao W; Zeng MS; Zhang X
Oncogene; 2020 Jan; 39(1):151-163. PubMed ID: 31462708
[TBL] [Abstract][Full Text] [Related]
13. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.
Wiesner T; Lee W; Obenauf AC; Ran L; Murali R; Zhang QF; Wong EW; Hu W; Scott SN; Shah RH; Landa I; Button J; Lailler N; Sboner A; Gao D; Murphy DA; Cao Z; Shukla S; Hollmann TJ; Wang L; Borsu L; Merghoub T; Schwartz GK; Postow MA; Ariyan CE; Fagin JA; Zheng D; Ladanyi M; Busam KJ; Berger MF; Chen Y; Chi P
Nature; 2015 Oct; 526(7573):453-7. PubMed ID: 26444240
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.
Kodama T; Motoi N; Ninomiya H; Sakamoto H; Kitada K; Tsukaguchi T; Satoh Y; Nomura K; Nagano H; Ishii N; Terui Y; Hatake K; Ishikawa Y
J Thorac Oncol; 2014 Nov; 9(11):1638-46. PubMed ID: 25144242
[TBL] [Abstract][Full Text] [Related]
16. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
17. EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
Vaishnavi A; Schubert L; Rix U; Marek LA; Le AT; Keysar SB; Glogowska MJ; Smith MA; Kako S; Sumi NJ; Davies KD; Ware KE; Varella-Garcia M; Haura EB; Jimeno A; Heasley LE; Aisner DL; Doebele RC
Cancer Res; 2017 Jul; 77(13):3551-3563. PubMed ID: 28428274
[TBL] [Abstract][Full Text] [Related]
18. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
[TBL] [Abstract][Full Text] [Related]
19. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
20. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
